Glenmark Pharmaceuticals (GLENMARK) investor relations material

Strategic vision and growth roadmap

• Aims to become a leading, research-driven global pharmaceutical company with a diversified platform and presence in over 80 countries, focusing on Dermatology, Respiratory, and Oncology.

• Targets therapy area dominance in India and emerging markets, scaling generics in the US, and expanding specialty products in Europe by 2030.

• Plans to globally commercialize 1-2 multispecific innovative oncology products and achieve leadership in US respiratory and injectables by 2035.

• Focuses on differentiated branded launches and innovation, with over 60% of revenue from branded markets and a shift toward >70% branded by FY30.

Operational and regional performance

• India business outpaces market growth, ranking top 5 in key therapy areas and launching multiple mega-brands.

• Emerging markets show strong expansion, with leadership in respiratory and dermatology, and no reliance on a single market.

• Europe sees rapid branded portfolio growth and successful respiratory launches, with further expansion planned.

• North America maintains a top 3 position in most commercialized products, expanding in respiratory, injectables, and branded segments.

Innovation and pipeline development

• Over 26 years of innovation, with 16+ molecules in clinical development and 10 out-licensing deals since 2004.

• IGI’s BEAT® platform drives next-gen multispecific antibody development, targeting oncology and immunology indications.

• ISB 2001 trispecific T-cell engager in multiple myeloma is advancing in Phase 1, with promising safety and efficacy data.

• ISB 2301, a first-in-class multispecific immune cell activator for solid tumors, is nearing IND filing.